We are an international network of healthcare professionals, researchers and consumers producing systematic reviews of evidence for treating cystic fibrosis and other genetic disorders (haemoglobinopathies. coagulopathies and inborn errors of metabolism). Our editorial base is located in Liverpool, UK.
New overview of Cochrane Reviews on blood transfusion in sickle cell disease
Red blood cell transfusions are used to treat complications of SCD, e.g. acute chest syndrome, as either a single transfusion episode or part of a regular long-term transfusion programme. We have published an overview summarising the evidence in Cochrane Reviews of the effectiveness and safety of red blood cell transfusions, available here. The review includes comparisons of short- or long-term transfusions versus standard care, disease-modifying agents, different transfusion strategies and long-term transfusion programs versus transfusions to treat specific complications.
New review on correctors for Class II CFTR mutations in cystic fibrosis
We have published the latest evidence for CFTR correctors such as lumacftor-ivacaftor (marketed as OrkambiTM) and tezacaftor-ivacaftor (marketed as SymdekoTM) in a new review now available to read here. We have included 13 randomised controlled trials with a total of 2215 people with cystic fibrosis of all ages. The review looks at both monotherapy and combination therapy and presents evidence for clinical benefits as well as potential harms. In this fast-moving field of research, new trials are frequently being published and we intend to update this review regularly to provide the cystic fibrosis population with the latest evidence base.
We have summarised our review in a podcast available here.
|Latest output published on The Cochrane Library|
|On Issue 7 2018 of The Cochrane Library we have published a total of 181 reviews and 27 protocols. There are also 9 registered titles currently progressing to protocol status. The production of these reviews involves a network of over 1000 contributors (authors, consumers and referees) throughout the world. We very much welcome interest from new consumers, referees and potential reviewers. Further information can be obtained by contacting the group.|
|By getting involved in these priority setting partnerships you can help shape future research. We have already successfully been invovled in a priority setting partnership for CF and you can see the results here. A new priority setting partnership is now open for bleeding disorders and if you have a bleeding disorder and are 8 years of age or older, or if you are a carer for someone with a bleeding disorder, we strongly encourage you to participate. Clinicians and other health professionals are welcome to participate too. More information can be found here.|